Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Gsk Plc (GSK.LN)

Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 65,432,533
  • Shares Outstanding, K 4,078,064
  • Annual Sales, $ 30,328 M
  • Annual Income, $ 4,928 M
  • 60-Month Beta N/A
  • Price/Sales 2.15
  • Price/Cash Flow 8.61
  • Price/Book 4.73
Trade GSK.LN with:
  • Price/Earnings ttm 14.75
  • Earnings Per Share ttm 1.09
  • Most Recent Earnings $0.25 on 05/01/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.58 (3.74%)
  • Most Recent Dividend 0.150 on 05/16/24
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,588.000 +1.32%
on 06/04/24
1,808.500 -11.03%
on 05/23/24
-166.001 (-9.35%)
since 05/17/24
3-Month
1,575.000 +2.16%
on 04/19/24
1,823.500 -11.76%
on 05/16/24
-51.801 (-3.12%)
since 03/18/24
52-Week
1,302.600 +23.52%
on 07/11/23
1,823.500 -11.76%
on 05/16/24
+244.399 (+17.91%)
since 06/16/23
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
Wall Street - shutterstock_1321462400
Stocks Set to Open Higher as Rate Cut Bets Firm, U.S. Jobs Data in Focus Barchart - Mon Jun 3, 4:33AM CDT

June S&P 500 E-Mini futures (ESM24) are up +0.25%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.37% this morning as speculation over interest rate cuts by major central banks heightened appetite...

ESM24 : 5,482.25 (+0.07%)
NQM24 : 19,906.75 (-0.07%)
CZR : 36.43 (+0.86%)
ZS : 181.20 (-1.72%)
GPS : 25.64 (-1.38%)
MDB : 221.60 (-0.93%)
CRWD : 392.18 (+0.45%)
GTLB : 43.23 (-0.46%)
HPE : 22.56 (+4.78%)
BBWI : 41.88 (-0.55%)
LULU : 314.49 (+0.50%)
DLTR : 107.85 (-0.74%)
Moderna Investors Just Got Some Bullish News Motley Fool - Mon Jun 3, 3:50AM CDT

This news could be worth billions...

GSK.LN : 1,607.000 (+0.44%)
PFE : 27.21 (+0.85%)
MRNA : 132.78 (-3.71%)
Is This a Setback for Moderna? Motley Fool - Tue May 14, 5:35AM CDT

Moderna's shares slipped after the company announced the delay.

PFE : 27.21 (+0.85%)
GSK.LN : 1,607.000 (+0.44%)
MRNA : 132.78 (-3.71%)
Drug Patents
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition Associated Press - Tue Apr 30, 4:36PM CDT

The Federal Trade Commission is challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic

AZN.LN : 12,400.000 (-0.23%)
AZN : 78.96 (-0.44%)
GSK.LN : 1,607.000 (+0.44%)
GSK : 40.87 (+0.52%)
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. Motley Fool - Tue Apr 9, 5:35AM CDT

These companies are close to launching new products that could supercharge revenue.

LLY : 889.26 (+0.48%)
PFE : 27.21 (+0.85%)
GSK.LN : 1,607.000 (+0.44%)
MRNA : 132.78 (-3.71%)
VRTX : 473.06 (-0.13%)
RSV Drug
Babies should get recently approved drug for RSV, CDC says Associated Press - Thu Aug 3, 2023

U.S. health officials are recommending that babies get a recently approved drug to protect them against a respiratory virus

PFE : 27.21 (+0.85%)
GSK.LN : 1,607.000 (+0.44%)
GSK : 40.87 (+0.52%)
AZN.LN : 12,400.000 (-0.23%)
AZN : 78.96 (-0.44%)
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Newswire.ca - Wed Jun 28, 2023

/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...

BLU : 14.74 (unch)
GSK.LN : 1,607.000 (+0.44%)
GSK : 40.87 (+0.52%)
BLU.TO : 19.48 (-0.10%)
Author
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results MarketBeat - Mon May 8, 2023

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug

SGEN : 228.74 (-0.07%)
AZN : 78.96 (-0.44%)
IMGN : 31.23 (unch)
GSK : 40.87 (+0.52%)
GSK.LN : 1,607.000 (+0.44%)
PFE : 27.21 (+0.85%)
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment ACN Newswire - Thu May 4, 2023

International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment

FOSUF : 0.5901 (+10.30%)
FOSUY : 14.5300 (+1.25%)
GSK.LN : 1,607.000 (+0.44%)
GSK : 40.87 (+0.52%)
JNJ : 145.49 (-0.32%)
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health Business Wire - Tue Apr 18, 2023

GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical...

BLU : 14.74 (unch)
GSK : 40.87 (+0.52%)
GSK.LN : 1,607.000 (+0.44%)
BLU.TO : 19.48 (-0.10%)
More news for this symbol

Barchart Technical Opinion

Weak buy

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 1,636.665
2nd Resistance Point 1,624.833
1st Resistance Point 1,612.416
Last Price 1,607.000
1st Support Level 1,588.167
2nd Support Level 1,576.335
3rd Support Level 1,563.918

See More

52-Week High 1,823.500
Fibonacci 61.8% 1,624.516
Last Price 1,607.000
Fibonacci 50% 1,563.050
Fibonacci 38.2% 1,501.584
52-Week Low 1,302.600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot